Ascendis Pharma As Stock Market Value
ASND Stock | USD 122.64 1.74 1.40% |
Symbol | Ascendis |
Ascendis Pharma AS Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.91) | Revenue Per Share 5.595 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (8.18) |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Ascendis Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ascendis Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ascendis Pharma.
10/23/2024 |
| 11/22/2024 |
If you would invest 0.00 in Ascendis Pharma on October 23, 2024 and sell it all today you would earn a total of 0.00 from holding Ascendis Pharma AS or generate 0.0% return on investment in Ascendis Pharma over 30 days. Ascendis Pharma is related to or competes with Apellis Pharmaceuticals, BeiGene, Akero Therapeutics, Blueprint Medicines, Replimune, Nuvalent, and Ventyx Biosciences. Ascendis Pharma AS, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs More
Ascendis Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ascendis Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ascendis Pharma AS upside and downside potential and time the market with a certain degree of confidence.
Information Ratio | (0.06) | |||
Maximum Drawdown | 22.16 | |||
Value At Risk | (3.56) | |||
Potential Upside | 3.27 |
Ascendis Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ascendis Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ascendis Pharma's standard deviation. In reality, there are many statistical measures that can use Ascendis Pharma historical prices to predict the future Ascendis Pharma's volatility.Risk Adjusted Performance | (0.02) | |||
Jensen Alpha | (0.19) | |||
Total Risk Alpha | (0.49) | |||
Treynor Ratio | (0.17) |
Ascendis Pharma AS Backtested Returns
Ascendis Pharma AS secures Sharpe Ratio (or Efficiency) of -0.0429, which signifies that the company had a -0.0429% return per unit of standard deviation over the last 3 months. Ascendis Pharma AS exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Ascendis Pharma's mean deviation of 1.97, and Risk Adjusted Performance of (0.02) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.74, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Ascendis Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ascendis Pharma is expected to be smaller as well. At this point, Ascendis Pharma AS has a negative expected return of -0.14%. Please make sure to confirm Ascendis Pharma's treynor ratio, and the relationship between the standard deviation and kurtosis , to decide if Ascendis Pharma AS performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.24 |
Weak predictability
Ascendis Pharma AS has weak predictability. Overlapping area represents the amount of predictability between Ascendis Pharma time series from 23rd of October 2024 to 7th of November 2024 and 7th of November 2024 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ascendis Pharma AS price movement. The serial correlation of 0.24 indicates that over 24.0% of current Ascendis Pharma price fluctuation can be explain by its past prices.
Correlation Coefficient | 0.24 | |
Spearman Rank Test | 0.02 | |
Residual Average | 0.0 | |
Price Variance | 3.66 |
Ascendis Pharma AS lagged returns against current returns
Autocorrelation, which is Ascendis Pharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Ascendis Pharma's stock expected returns. We can calculate the autocorrelation of Ascendis Pharma returns to help us make a trade decision. For example, suppose you find that Ascendis Pharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
Timeline |
Ascendis Pharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Ascendis Pharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Ascendis Pharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Ascendis Pharma stock over time.
Current vs Lagged Prices |
Timeline |
Ascendis Pharma Lagged Returns
When evaluating Ascendis Pharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Ascendis Pharma stock have on its future price. Ascendis Pharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Ascendis Pharma autocorrelation shows the relationship between Ascendis Pharma stock current value and its past values and can show if there is a momentum factor associated with investing in Ascendis Pharma AS.
Regressed Prices |
Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Ascendis Pharma Correlation, Ascendis Pharma Volatility and Ascendis Pharma Alpha and Beta module to complement your research on Ascendis Pharma. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Ascendis Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.